Literature DB >> 16804333

Prevalence of multiple sclerosis in Isfahan, Iran.

Masoud Etemadifar1, Mohsen Janghorbani, Vahid Shaygannejad, Fereshteh Ashtari.   

Abstract

BACKGROUND: The prevalence of multiple sclerosis (MS) shows considerable variability all over the world. According to Kurtzke, Iran is considered to have a low prevalence.
OBJECTIVE: To estimate the period prevalence and risk factors of MS in Isfahan, central part of Iran.
METHODS: A cross-sectional case register study conducted between 2004 and 2005. In the province of Isfahan, Iran, all patients known to have definite MS during 2004 and 2005, being alive and resident within Isfahan as well as being a member of the Isfahan MS Association were included in the study. Demographic and case-related information was recorded. 1,391 definite MS patients (308 men and 1,083 women) from the Isfahan MS Association, Iran, have been identified. The disease was confirmed using clinical information and MRI findings by a neurologist and radiologist. The patients were evaluated by interview and a questionnaire. Population data were obtained from the year 1999 Iran Census. The mean (SD) age of the participants was 32.5 (9.3) years with a mean (SD) duration of the disease of 6.4 (5.1) years for men and 6.9 (5.3) years for women.
RESULTS: The period prevalence of MS was 35.5 per 100,000 [95% confidence interval (CI) 33.6-37.3] in a population of 3,923,255, with a higher rate in women than men [54.5 (95% CI: 51.1-57.8) for women and 14.9 (95% CI: 13.3-16.6) for men]. The female/male ratio was 3.6 (95% CI: 3.2-4.1). The direct age-adjusted period prevalence was 59.5 per 100,000 (95% CI: 44.8-75.2) for women and 17.0 per 100,000 (95% CI: 8.9-25.1) for men. MS rates were highest among 30- to 39-year-olds and decreased with increasing age. Sensory and visual disturbances were the most common initial presentations with a prevalence of 51.1% (95% CI: 48.4-53.7) and 47.0% (95% CI: 44.4-49.7), respectively.
CONCLUSION: Isfahan could be considered as an area with a medium to high risk of MS. This is in sharp contrast with the gradient hypothesis.

Entities:  

Mesh:

Year:  2006        PMID: 16804333     DOI: 10.1159/000094235

Source DB:  PubMed          Journal:  Neuroepidemiology        ISSN: 0251-5350            Impact factor:   3.282


  39 in total

1.  Inflammatory profile, age of onset, and the MTHFR polymorphism in patients with multiple sclerosis.

Authors:  Sudabeh Alatab; Arash Hossein-nezhad; Khadijeh Mirzaei; Fatemeh Mokhtari; Gholamreza Shariati; Azam Najmafshar
Journal:  J Mol Neurosci       Date:  2010-12-29       Impact factor: 3.444

2.  Differential diagnosis of white matter diseases in the tropics: An overview.

Authors:  Lekha Pandit
Journal:  Ann Indian Acad Neurol       Date:  2009-01       Impact factor: 1.383

Review 3.  Recent insights in the epidemiology of autoimmune diseases: improved prevalence estimates and understanding of clustering of diseases.

Authors:  Glinda S Cooper; Milele L K Bynum; Emily C Somers
Journal:  J Autoimmun       Date:  2009-10-09       Impact factor: 7.094

4.  Marked differences in prevalence of multiple sclerosis between ethnic groups in Oslo, Norway.

Authors:  Catherine Smestad; Leiv Sandvik; Trygve Holmoy; Hanne Flinstad Harbo; Elisabeth Gulawson Celius
Journal:  J Neurol       Date:  2007-12-20       Impact factor: 4.849

5.  Multiple sclerosis in Isfahan, Iran: Past, Present and Future.

Authors:  Masoud Etemadifar; Seyed-Hossein Abtahi
Journal:  Int J Prev Med       Date:  2012-05

6.  Cost-effectiveness of different interferon beta products for relapsing-remitting and secondary progressive multiple sclerosis: Decision analysis based on long-term clinical data and switchable treatments.

Authors:  Shekoufeh Nikfar; Abbas Kebriaeezadeh; Rassoul Dinarvand; Mohammad Abdollahi; Mohammad-Ali Sahraian; David Henry; Ali Akbari Sari
Journal:  Daru       Date:  2013-06-22       Impact factor: 3.117

7.  Monitoring of active human herpes virus 6 infection in Iranian patients with different subtypes of multiple sclerosis.

Authors:  Nourollah Ramroodi; Nima Sanadgol; Zohre Ganjali; Abbas Ali Niazi; Vida Sarabandi; Ali Moghtaderi
Journal:  J Pathog       Date:  2013-01-22

8.  The global prevalence of familial multiple sclerosis: an updated systematic review and meta-analysis.

Authors:  Naeim Ehtesham; Maryam Zare Rafie; Meysam Mosallaei
Journal:  BMC Neurol       Date:  2021-06-28       Impact factor: 2.474

9.  Preliminary study related the incidence of methylprednisolone pulse therapy in patients visited multiple sclerosis clinic located at the isfahan kashani hospital.

Authors:  Zahra Tolou-Ghamari; Vahid Shaygannejad; Fereshteh Ashtari
Journal:  Int J Prev Med       Date:  2013-05

10.  Color blindness among multiple sclerosis patients in Isfahan.

Authors:  Vahid Shaygannejad; Khodayar Golabchi; Alireza Dehghani; Fereshteh Ashtari; Sepehr Haghighi; Mahsa Mirzendehdel; Majid Ghasemi
Journal:  J Res Med Sci       Date:  2012-03       Impact factor: 1.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.